At a glance
ClinicalIndex Comparison RecordN/ACompleted· 230 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CLINICOPATHOLOGICAL FEATURES OF NON-SMALL CELL LUNG CANCER PATIENTS ASSOCIATED WITH THE CHOROMOSOME 2p (EML4-ALK) INVERSION IN MEXICAN POPULATION.
In Brief
An observational study for Non Small-cell Lung Cancer. Completed, enrolled 230 participants across 1 site.
Detailed Summary
Because ALK-positive lung cancer constitutes less than 5% of all lung cancers, it is critically important to select those patients who are more likely to have the ALK mutation. Clinical characteristics of patients with mutations in the target gene should also be known, so that the incidence of a given target mutation is established in a specific population. There is not incidence known in Mexican population, but it is believed it is greater.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small-cell Lung Cancer
CountriesMexico
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedAug 2012
Primary CompletionSep 2014
TodayJul 2026
First PostedAug 10, 2012
Enrollment StartFeb 1, 2011
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 13.9 years ago